SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D

被引：0
|
作者：
Javier Escalada
机构：
[1] Clínica Universidad de Navarra,Department of Endocrinology and Nutrition
[2] Instituto de Salud Carlos III,CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN)
来源：
Diabetes Therapy | 2022年 / 13卷
关键词：
Type 2 diabetes; SGLT2 inhibitors; Cardiorenal; Cardiovascular disease; Kidney disease; Heart failure; Morbidity; Mortality; Chronic kidney disease; Cardiorenal continuum;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 3
页数：2
相关论文
共 50 条
  • [1] SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
    Escalada, Javier
    DIABETES THERAPY, 2022, 13 (SUPPL 1) : 1 - 3
  • [2] SGLT2 inhibitors reduce gout attacks in gout patients with T2D
    Di Lellis, Maddalena Angela
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2025, 150 (01/02) : 12 - 12
  • [3] SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
    Guntram Schernthaner
    Heinz Drexel
    Evgeny Moshkovich
    Birute Zilaitiene
    Emil Martinka
    Leszek Czupryniak
    Tamás Várkonyi
    Andrej Janež
    Kristine Ducena
    Katarina Lalić
    Tsvetalina Tankova
    Martin Prázný
    Lea Smirčić Duvnjak
    Olga Sukhareva
    Harald Sourij
    BMC Endocrine Disorders, 19
  • [4] SGLT2 inhibitors in T2D and associated comorbidities differentiating within the class
    Schernthaner, Guntram
    Drexel, Heinz
    Moshkovich, Evgeny
    Zilaitiene, Birute
    Martinka, Emil
    Czupryniak, Leszek
    Varkonyi, Tamas
    Janez, Andrej
    Ducena, Kristine
    Lalic, Katarina
    Tankova, Tsvetalina
    Prazny, Martin
    Duvnjak, Lea Smircic
    Sukhareva, Olga
    Sourij, Harald
    BMC ENDOCRINE DISORDERS, 2019, 19 (1)
  • [5] Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes
    Nazari, Somayeh
    Mirkhani, Hossein
    CURRENT DIABETES REVIEWS, 2023, 19 (08)
  • [6] SGLT2 inhibitors in cancer patients: a paradigm shift in cardio-oncology?
    Cautela, Jennifer
    Alexandre, Joachim
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2025,
  • [7] Roles for SGLT2 Inhibitors in Cardiorenal Disease
    Green, Jennifer B.
    McCullough, Peter A.
    CARDIORENAL MEDICINE, 2022, 12 (03) : 81 - 93
  • [8] Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?
    Ferreira, Joao Pedro
    Mendonca, Luis
    Neves, Joao Sergio
    JOURNAL OF CARDIAC FAILURE, 2024, 30 (09) : 1181 - 1182
  • [9] A Paradigm Shift in Diabetes Therapy - Dapagliflozin and Other SGLT2 Inhibitors
    Chao, Edward C.
    DISCOVERY MEDICINE, 2011, 11 (58) : 255 - 263
  • [10] Class effects of SGLT2 inhibitors on cardiorenal outcomes
    Kluger, Aaron Y.
    Tecson, Kristen M.
    Lee, Andy Y.
    Lerma, Edgar V.
    Rangaswami, Janani
    Lepor, Norman E.
    Cobble, Michael E.
    McCullough, Peter A.
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (01)
12345